      |
|
||||||||
|
Dr. Egbert Oosterwijk
Research interests include targeted therapy of urologic malignancies with special emphasis on monoclonal antibodies and antibody fusion molecules as new therapeutic reagents. Major current projects include detection of differentially expressed molecules in different responder populations and in prostate cancer (versus normal prostate and other normal tissues) through array analyses and proteome analyses, and the development of (redirected) tumour-specific adenoviral vectors. |
||||||||
|
Recent key publications Jongmans W, Tiemessen DM, van Vlodropo IJ, Mulders PF, Oosterwijk E: Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails. J Immunother. 28:480-7,
Van Houwelingen KP, van Dijk BA, Hulsbergen-van de Kaa CA, Schouten LJ, Gorissen HJ, Schalken JA, van den Brandt PA, Oosterwijk E: Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. BMC Cancer 5:57, 2005 Van Schaijk FG, Oosterwijk E, Soede AC, Broekema M, Frielink C, McBride WJ, Goldenberg DM, Corstens FH, Boerman OC: Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody. Clin Cancer Res 11: 7130s-7136s, 2005 |
||||||||
